港股異動丨康希諾生物(6185.HK)反彈近10% 獲納入MSCI全球標準中國指數今日收盤後生效
格隆匯5月29日丨康希諾生物(6185.HK)漲近10%,報179.3港元,總市值399億港元。康希諾生物於5月21日見頂285.8港元至本週三低見152港元,累計最大跌幅近47%。MSCI明晟此前公佈半年度指數成分股檢討結果顯示,康希諾生物獲納入MSCI全球標準中國指數,該變動將於今日收盤後生效。大摩近日發佈報告表示,目前估計康希諾生物-B(06185)疫苗的成功率在60%;預計其疫苗將在今年年底或明年年初獲批。該行將其目標價由102港元上調153%至258港元,維持“增持”評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.